Program
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200
Also written as “SKB315 for injection” and “MK-1200”.
Its studies are led by 2 companies.
Drug pageAnti-Claudin 18.2 Antibody-drug Conjugate MK-1200: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceuticalits history only | 22 open or running | phase 2since May 20, 2026 | Apr 21, 2022 | Jun 30, 2028phase 2 · NCT07609667 |
| Merckits history only | 10 open or running | phase 2since Jan 26, 2024 | Jan 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 21, 2022First study: phase 1 study in Advanced Solid TumorsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT05367635 · 246 planned · China
- Jan 26, 2024Merck’s first study: phase 2 study in Advanced Solid TumorsNew to MerckMerck · NCT06242691 · 13 enrolled · United States, Australia, Chile and more
- May 20, 2026Phase 2 study in Gastroesophageal Junction AdenocarcinomaPhase 2 reachedSichuan Kelun Pharmaceutical · NCT07609667 · 80 planned · China
Ahead
- Jun 30, 2028Primary completion: phase 2 study in Gastroesophageal Junction AdenocarcinomaSichuan Kelun Pharmaceutical · NCT07609667
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) that is site-specifically ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07609667Gastroesophageal Junction Adenocarcinoma · China | 2 | Not yet recruiting | Sichuan Kelun Pharmaceutical | Jun 30, 2028 | 80 |
| NCT06242691Advanced Solid Tumors · United States, Australia, Chile and more | 2 | Completed | Merck | Jun 17, 2025 | 13 |
| NCT05367635Advanced Solid Tumors · China | 1 | Recruiting | Sichuan Kelun Pharmaceutical | Jun 30, 2026 | 246 |
How it is read
Names in the registry
- “SKB315 for injection”, 2 entries
- “MK-1200”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.